Cite
HARVARD Citation
Smith, J. et al. (2020). Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet. 8 (8), pp. 775-785. [Online].